Once-monthly Abilify gains FDA nod

02/28/2013 | Bloomberg Businessweek

The FDA has granted Otsuka Holdings and H. Lundbeck approval for Abilify Maintena, a once-a-month injection for patients with schizophrenia. The drug was associated with significant delays in relapse compared with placebo, the company said.

View Full Article in:

Bloomberg Businessweek

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Claims Director
PacificSource
Springfield, OR
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA